CoChat

Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies

Open access
Renneville, Aline, Gasser, Jessica A., Grinshpun, Daniel E., Jean Beltran, Pierre M., Udeshi, Namrata D., Matyskiela, Mary E., Clayton, Thomas, McConkey, Marie, Viswanathan, Kaushik, Tepper, Alexander, Guirguis, Andrew A., Sellar, Rob S., Cotteret, Sophie, Marzac, Christophe, Saada, Véronique, De Botton, Stéphane, Kiladjian, Jean-Jacques, Cayuela, Jean-Michel, Rolfe, Mark, Chamberlain, Philip P., Carr, Steven A., Ebert, Benjamin L. · 2021 · Blood Cancer Discovery
Cited by 48

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Thalidomide analogues exert their therapeutic effects by binding to the CRL4CRBN E3 ubiquitin ligase, promoting ubiquitination and subsequent proteasomal degradation of specific protein substrates. Drug-induced degradation of IKZF1 and IKZF3 in B-cell malignancies demonstrates the clinical utility of targeting disease-relevant transcription factors for degradation. Here, we found that avadomide (CC-122) induces CRBN-dependent ubiquitination and proteasomal degradation of ZMYM2 (ZNF198), a transcription factor involved in balanced chromosomal rearrangements with FGFR1 and FLT3 in aggressive forms of hematologic malignancies. The minimal drug-responsive element of ZMYM2 is a zinc-chelating MYM domain and is contained in the N-terminal portion of ZMYM2 that is universally included in the derived fusion proteins. We demonstrate that avadomide has the ability to induce proteasomal degradation of ZMYM2–FGFR1 and ZMYM2–FLT3 chimeric oncoproteins, both in vitro and in vivo. Our findings suggest that patients with hematologic malignancies harboring these ZMYM2 fusion proteins may benefit from avadomide treatment. Significance: We extend the potential clinical scope of thalidomide analogues by the identification of a novel avadomide-dependent CRL4CRBN substrate, ZMYM2. Avadomide induces ubiquitination and degradation of ZMYM2–FGFR1 and ZMYM2–FLT3, two chimeric oncoproteins involved in hematologic malignancies, providing a proof of concept for drug-induced degradation of transcription factor fusion proteins by thalidomide analogues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-20-0105

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 48

Metadata

Authors
Renneville, A., Gasser, J. A., Grinshpun, D. E., Jean Beltran, P. M., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M., Viswanathan, K., Tepper, A., Guirguis, A. A., Sellar, R. S., Cotteret, S., Marzac, C., Saada, V., De Botton, S., Kiladjian, J.-J., Cayuela, J.-M., Rolfe, M., Chamberlain, P. P., Carr, S. A., & Ebert, B. L.
Venue
Blood Cancer Discovery
Published
2021-03-10
Volume
2
Issue
3
Pages
250-265
ISSN
  • 2643-3230 (ISSN-L)
  • 2643-3249
OpenAlex
W3135051742
Cited by
48
References
19
FWCI
1.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/2643-3230.bcd-20-0105
The paper
Renneville, A., Gasser, J. A., Grinshpun, D. E., Jean Beltran, P. M., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M., Viswanathan, K., Tepper, A., Guirguis, A. A., Sellar, R. S., Cotteret, S., Marzac, C., Saada, V., De Botton, S., Kiladjian, J.-J., Cayuela, J.-M., Rolfe, M., . . . Ebert, B. L. (2021). Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-20-0105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.